NASDAQ: INSM

Insmed (INSM) Stock Analysis & Forecast

Nov 13 close

$121.16+3.09 (+2.6%)

Gekko Brief

AI summaryNov 9 close

This week's news centers on Insmed's third-quarter update, in which the company raised full-year 2026 guidance for BRINSUPRI and ARIKAYCE after exceeding $1 billion in total company revenue year-to-date, with BRINSUPRI surpassing $1 billion in revenue across its first four full quarters. Analyst activity followed, with H.C. Wainwright initiating coverage with a buy rating and a $220.00 price target, citing peak sales guidance exceeding $14 billion across the respiratory portfolio, while another commentary set fair value near $99 against a $110 share price. Management also announced presentations at the Jefferies Global Healthcare Conference on 16 November and the Evercore 9th Annual Healthcare Conference on 1 December.

Shares closed at $116.10, up 1.5%, sitting between the 50-day moving average of $111.16 and the 200-day average of $123.95. The GekkoIndex reads 52.2, placing the stock in the Neutral zone, with the five-day change at -0.9. Price sits 19% below Gekko Fair Value of $143.31.

The next earnings date falls on 18 February 2027, 100 days out and beyond a typical 20-trading-day holding window. Over the last 30 days, one unusual options signal appeared, with call premium of $3,334,530 against no put premium. Seasonality over 5 years shows the next 20 trading days averaging a 1.8% return, higher in 4 of those years. Consensus among 17 firms stands at 16 buy and 1 hold, with a consensus target of $194.18.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Insmed price vs fair value

$143.59$121.16Nov ’25May ’26Nov ’26
Close $121.16200-day averageGekko Fair Value $143.59

Insmed quick facts

Market cap
$26.58B
P/E ratio
—
Forward P/E
106.4
EPS, TTM
−$2.81
Revenue, TTM
$1.52B
Profit margin
-39.9%
Dividend yield
—
Beta
0.81
Volume
1.54M avg 3.77M
1-year return
−37.7%
Typical daily move
±4.8%
Typical 20-day move
±8.1%
50-day average
$110.82
200-day average
$123.16
Next earnings
Feb 18 before open
Shares outstanding
219.4M
52-week range
$90.39$212.75

Insmed swing-trade checklist

Insmed scores 4 supportive, 2 mixed and 0 headwinds across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

4 supportive2 mixed0 headwinds

  • Trendmixed

    Averages disagree

    Close $121.16 sits between the 50-day ($110.82) and 200-day ($123.16) averages, or the averages disagree.

    See the chart
  • GekkoIndexmixed

    50.9, Neutral

    Reading 50.9 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuesupportive

    15.6% below

    Price is 15.6% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 30 days: 1 unusual options signal.

    See smart money
  • Earnings risksupportive

    Reports in 95 days

    Next report Feb 18, 2027, 95 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +2.9% on average

    From this point in the calendar, the next 20 trading days averaged +2.9% over 5 years, rising in 4 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Insmed stock chart and price history

Insmed closed at $121.16 on Nov 13, 2026, −37.7% over the past year, inside a 52-week range of $90.39 to $212.75.

Close50-day average200-day averageVolume
Insmed share price, past year, with 50-day and 200-day moving averages and volume$100$150$175$200DecJan 2026FebMarAprMayJunJulAugSepOctNov121.16

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+22.1%
3 months
−5.6%
6 months
+11.0%
1 year
−37.7%
The full INSM chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open INSM in Gekko

Follow Insmed through every session

Put INSM on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track INSM in GekkoFree for 7 days. No credit card required.

About Insmed

Insmed is a biopharmaceutical company that develops treatments for people with serious and rare diseases. Its approved product, ARIKAYCE, is used by adult patients with Mycobacterium avium complex lung disease, given as part of a wider antibacterial treatment plan. The company is best known for this therapy alongside a pipeline of experimental treatments aimed at difficult-to-treat conditions.

Beyond its marketed product, Insmed is working on Brensocatib, an oral compound that inhibits an enzyme called dipeptidyl peptidase 1, being studied for bronchiectasis and other conditions driven by neutrophils. It is also developing an inhaled form of a treprostinil palmitil prodrug, intended for pulmonary arterial hypertension and other rare lung diseases. Its work centers on patients whose conditions are uncommon and often underserved by existing treatment options.

Insmed was founded in 1988 and is headquartered in Bridgewater, New Jersey. Its shares are listed on the NASDAQ under the ticker INSM.

Listed
NASDAQ
Sector
Health technology
Industry
Pharmaceuticals: major
Website
insmed.com

Insmed GekkoIndex: the smart money zone

Insmed’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 50.9, in the Neutral zone, down 2.4 points over five sessions.

010050.9Neutral

Down 2.4 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying22+9.3%+10.2%+14.8%+57.7%
Accumulation259+2.3%+4.7%+7.7%+22.3%
Neutral (current zone)360+0.3%+1.1%+4.0%+13.1%
Distribution51+2.4%+4.7%+10.7%+21.1%
Selling10+3.2%+5.8%+8.0%+26.5%

Average INSM share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the INSM price, zone by zone.Track INSM in Gekko

Is Insmed stock overvalued? Gekko Fair Value

Insmed trades 15.6% below Gekko Fair Value of $143.59, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Insmed shares are worth, recalculated every trading day.

$143.59

Gekko Fair Value, Nov 14, 2026

15.6% Undervalued

At the end of Aug 2026 the price was 28.3% below the estimate.

Gekko Fair ValueShare price, month end
$144$121Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open INSM in Gekko

Insmed insider and Congress trading

No open-market insider purchases were filed for Insmed, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for INSM in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every INSM insider filing, plotted on the chart in Gekko.Open INSM in Gekko

Congress trades last 90 days

No trades in INSM were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for INSM, plotted on the chart in Gekko.Open INSM in Gekko

Unusual options activity last 30 days

1signal, 100% of the flagged premium in calls.

Latest: Bullish flow on Oct 23, $3.33M in unusual premium.

Hedge funds and billionaires quarter ended Jun 30

1of the funds Gekko tracks holds INSM.

1added0opened0trimmed0sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko

Insmed earnings: next date and track record

Insmed reports on Feb 18, 2027, before the open (95 days away), and beat the EPS estimate in 2 of its last 8 reports.

2 of 8reports beat the EPS estimate
±13.3%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

−3.3%Feb ’25−4.7%May ’25−1.5%Aug ’25+13.6%Oct ’25+9.1%Feb ’26−26.1%May ’26+32.4%Aug ’26+16.1%Oct ’26

Last earnings call, Oct 29, 2026 AI summary

What they said
Insmed exceeded $1 billion in total company revenue year-to-date in Q3 2026, with BRINSUPRI achieving blockbuster status surpassing $1 billion in revenue in its first four full quarters. The company raised full-year 2026 guidance for both BRINSUPRI and ARIKAYCE. Three lead respiratory assets are projected to collectively exceed $14 billion in peak sales, with BRINSUPRI alone targeting $7 billion-plus, TPIP over $6 billion, and ARIKAYCE over $1 billion.
Guidance
Full-year 2026 guidance raised for both BRINSUPRI and ARIKAYCE. Three respiratory assets projected to grow at 20%+ CAGR over 10+ years. ARIKAYCE expanded label possible next year with U.S. and Japan launches underway pending approval.
ReportedEPSSurpriseRevenueSurpriseMove
Oct 29, 2026−$0.46
est −$0.38
−20.2%$524.4M
est $500.4M
+4.8%+16.1%
Aug 6, 2026−$0.52
est −$0.69
+24.6%$425.5M
est $395.5M
+7.6%+32.4%
May 7, 2026−$0.76
est −$1.00
+24.0%$306.0M
est $300.8M
+1.7%−26.1%
Feb 19, 2026−$1.54
est −$1.07
−43.9%$263.8M
est $231.2M
+14.1%+9.1%
Oct 30, 2025−$1.75
est −$1.37
−27.7%$142.3M
est $115.4M
+23.3%+13.6%
Aug 7, 2025−$1.70
est −$1.30
−30.8%$107.4M
est $104.1M
+3.2%−1.5%
May 8, 2025−$1.42
est −$1.20
−18.3%$92.82M
est $91.47M
+1.5%−4.7%
Feb 20, 2025−$1.32
est −$1.23
−7.3%$104.4M
est $102.1M
+2.3%−3.3%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Insmed stock forecast and analyst price targets

Analysts’ average 12-month price target for Insmed is $194.18, +60.3% from the last close, from 17 firms rating the stock in the last 90 days.

$194.18consensus 12-month target, +60.3% from the last close
Low $158High $220
Buy16
Hold1
Sell0

Each firm’s latest rating in the last 90 days: 17 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 5Evercore ISIBuy, maintained$170+40.3%
Nov 4H.C. WainwrightBuy, initiated$220+81.6%
Nov 3Mizuho SecuritiesBuy, maintained$158+30.4%
Nov 2BMO CapitalBuy, maintained$192+58.5%
Nov 2BarclaysBuy, maintained$207+70.8%
+4.0%average 20-day move after past Neutral readings
+2.9%average move over the next 20 trading days in the last 5 years
±4.8%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Insmed seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Insmed averaged +2.9% across the last 5 years, rising in 4 of them.

Next 20 trading days, by year

−12.1%2021+5.4%2022+17.0%2023+0.5%2024+1.9%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days+0.2%2 of 5
Next 10 trading days+1.0%3 of 5
Next 15 trading days+2.3%4 of 5
Next 20 trading days+2.9%4 of 5
Next 30 trading days+1.4%1 of 5

For scale, INSM’s typical 20-trading-day move in either direction is about 8.1%.

Insmed market cap and key statistics

Insmed’s market cap is $26.58B and revenue of $1.52B over the last twelve months.

Valuation

Market cap
$26.58B
Forward P/E
106.4
EPS, TTM
−$2.81
Gekko Fair Value
$143.59

Trading

Volume
1.54M
Avg volume, 20 days
3.77M
52-week high
$212.75
52-week low
$90.39
Shares outstanding
219.4M

Financials

Revenue, TTM
$1.52B
Profit margin
-39.9%
Return on equity
-72.5%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
0.81
Typical daily move
±4.8%
Typical 20-day move
±8.1%

Insmed stock news this week

Coverage of Insmed this week reads positive: 2 positive, 1 neutral and 1 negative headlines.

News sentiment positive

Insmed peers

Insmed’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LLYEli Lilly+1.0%Neutral24.0% above
JNJJohnson & Johnson+0.3%Neutral4.4% above
ABBVAbbVie−0.5%Neutral23.7% above
MRKMerck+0.3%Neutral8.2% below
AZNAstraZeneca−0.2%Neutral34.6% below
PFEPfizer−0.1%Accumulation8.9% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Pharmaceuticals: major

Insmed stock FAQ

What is Insmed’s market cap?

Insmed’s market cap is $26.58B at the Nov 13, 2026 close of $121.16, with 219.4M shares outstanding.

What is the Insmed stock forecast?

The consensus analyst 12-month price target for Insmed is $194.18, +60.3% from the last close. Of the 17 firms that rated the stock in the last 90 days, 16 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Insmed stock overvalued or undervalued?

On Gekko’s estimate Insmed is undervalued: the Nov 13, 2026 close of $121.16 is 15.6% below Gekko Fair Value of $143.59. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Insmed report earnings next?

Insmed is expected to report on Feb 18, 2027, before the market opens (95 days away). Analysts expect earnings of −$0.31 per share on revenue of $601.7M. Insmed beat the earnings estimate in 2 of its last 8 reports, moving 13.3% on average across the report.

What is Insmed’s 52-week high and low?

Insmed’s 52-week high is $212.75 and its 52-week low is $90.39; it closed at $121.16 on Nov 13, 2026, −37.7% over the past year.

Is Insmed stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (fair value, smart money, earnings risk and seasonality), 2 as mixed (trend and gekkoindex). The checklist is a description of current data, not a recommendation.

Is there unusual options activity in Insmed?

Gekko flagged 1 unusual options signal in Insmed over the last 30 days, with $3.33M of flagged premium in calls and $0 in puts. The latest, bullish flow, was on Oct 23, 2026 with $3.33M in unusual premium. The signal-by-signal table is in Gekko.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Insmed the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.